LobbyingNational Marrow Donor Program lobbying by quarter
National Marrow Donor Program's latest lobbying report covers Q2 2026, at $300K. The four quarters Q4 2025–Q3 2026 total $900K. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Health Issues.
National Marrow Donor Program
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $900K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $130K | 1 |
| Q1 2023 | $210K | 1 |
| Q2 2023 | $180K | 1 |
| Q3 2023 | $160K | 1 |
| Q4 2023 | $210K | 1 |
| Q1 2024 | $260K | 1 |
| Q2 2024 | $220K | 1 |
| Q3 2024 | $200K | 1 |
| Q4 2024 | $240K | 1 |
| Q1 2025 | $300K | 1 |
| Q2 2025 | $270K | 1 |
| Q3 2025 | $290K | 1 |
| Q4 2025 | $280K | 1 |
| Q1 2026 | $320K | 1 |
| Q2 2026 | $300K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$1.1M · 15 reports
- Health issues$1.1M · 15 reports
- Transportation$704.7K · 9 reports
- Labor, antitrust and workplace$601.3K · 10 reports
- Consumer protection and safety$88K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Transportation Security Administration (TSA)9 reports
- U.S. Customs & Border Protection9 reports
- Federal Aviation Administration (FAA)5 reports
- Health Resources & Services Administration (HRSA)5 reports
- Consumer Financial Protection Bureau (CFPB)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseNational Marrow Donor Program | $3.6M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $300K |
| 04/20for Q1 | In-house | $320K |
| 01/20for Q4 2025 | In-house | $280K |
| 25/10/20for Q3 2025 | In-house | $290K |
| 25/07/17for Q2 2025 | In-house | $270K |
| 25/04/21for Q1 2025 | In-house | $300K |
| 25/01/21for Q4 2024 | In-house | $240K |
| 24/10/21for Q3 2024 | In-house | $200K |
| 24/07/22for Q2 2024 | In-house | $220K |
| 24/04/22for Q1 2024 | In-house | $260K |
| 24/01/22for Q4 2023 | In-house | $210K |
| 23/10/20for Q3 2023 | In-house | $160K |
| 23/07/26for Q2 2023 | In-house | $180K |
| 23/07/20for Q2 2023 | In-house | $230K |
| 23/04/20for Q1 2023 | In-house | $210K |
| 23/01/20for Q4 2022 | In-house | $130K |